Back to discover
Drug

Streptozocin

In clinical development
Emerging researchLate-stage developmentSteady momentum
Also known as 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose, 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose, D-GLUCOPYRANOSE, 2-DEOXY-2-(((METHYLNITROSOAMINO)CARBONYL)AMINO)-, Estreptozocina+9 more

2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose, 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose, D-GLUCOPYRANOSE, 2-DEOXY-2-(((METHYLNITROSOAMINO)CARBONYL)AMINO)-, Estreptozocina, N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff, N-D-Glucosyl-(2)-N'-nitrosomethylurea, Zanosar, Streptozocine, Streptozotocin, 1-METHYL-1-NITROSO-3-((2R,3R,4S,5R)-3,4,5,6-TETRAHYDROXY-1-OXOHEXAN-2-YL)UREA, 1-METHYL-1-NITROSO-3-((3R,4R,5S,6R)-2,4,5-TRIHYDROXY-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3-YL)UREA, Streptozocinium, Streptozocinum.

RxNorm10114ChEMBLCHEMBL1977579ATCL01AD04UNII5W494URQ81
4
Research papers
1
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Comparative Study on the Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction Induced Experimentally in Diabetic Rats

Clinical trial2024-11-30Completed · ClinicalTrials.gov

40 Hz light preserves synaptic plasticity and mitochondrial function in Alzheimer's disease model.

Research2024-11-06Scientific reports

Randomized Phase 2 Trial Of Two Chemotherapy Regimens Plus Or Minus Bevacizumab In Patients With Well Differentiated Pancreatic Neuroendocrine Tumors

Clinical trial2024-05-08Results expected Q4 2028 · ClinicalTrials.gov

Impaired Insulin Signaling Alters Mediators of Hippocampal Synaptic Dynamics/Plasticity: A Possible Mechanism of Hyperglycemia-Induced Cognitive Impairment.

Research2023-06-27Cells

Streptozotocin-Induced Diabetic Models in Mice and Rats.

Research2021-04-01Current protocols

First International Randomized Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment

Clinical trial2016-09-21Results posted · ClinicalTrials.gov

An Open Label Study to Evaluate the Effect of Avastin in Association With Chemotherapy on Progression-free Survival in Patients With Progressive Advanced/Metastatic Well-differentiated Digestive Endocrine Tumors of the Gastrointestinal Tract

Clinical trial2015-01-22Results posted · ClinicalTrials.gov

The use of animal models in diabetes research.

Research2012-06-01British journal of pharmacology

A Randomised Phase II Study Comparing Capecitabine Plus Streptozocin With or Without Cisplatin Chemotherapy as Treatment for Unresectable or Metastatic Neuroendocrine Tumors

Clinical trial2009-12-01Completed · ClinicalTrials.gov

Phase II Study of Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors

Clinical trial2008-03-01Terminated · ClinicalTrials.gov

Phase I Study of Combination Immunochemotherapy in Patients With Advanced Colorectal Carcinoma

Clinical trial2002-08-01Completed · ClinicalTrials.gov

Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms

Clinical trial1998-07-01Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Streptozocin
Aliases & brands
2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranoseD-GLUCOPYRANOSE, 2-DEOXY-2-(((METHYLNITROSOAMINO)CARBONYL)AMINO)-EstreptozocinaN-D-Glucosyl-(2)-N'-nitrosomethylharnstoffN-D-Glucosyl-(2)-N'-nitrosomethylureaZanosarStreptozocineStreptozotocin1-METHYL-1-NITROSO-3-((2R,3R,4S,5R)-3,4,5,6-TETRAHYDROXY-1-OXOHEXAN-2-YL)UREA1-METHYL-1-NITROSO-3-((3R,4R,5S,6R)-2,4,5-TRIHYDROXY-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3-YL)UREAStreptozociniumStreptozocinum
RxNorm CUI
10114
ChEMBL ID
CHEMBL1977579
ATC codes
L01AD04
UNII
5W494URQ81

Clinical trials

8 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
8
registered trials across all phases
LATEST COMPLETION 2024
1
Active studies
2
Late-stage (III+)
6
Completed
1
Discontinued
PHASE DISTRIBUTIONn = 8
Phase 11Phase 25Phase 31Phase 41

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Comparative Study on the Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction Induced Experimentally in Diabetic Rats

CompletedPH IVAl-Azhar Universityn=502024

First International Randomized Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment

CompletedPH IIICollaborative Group for Adrenocortical Carcinoma Treatmentn=3042010

Recent completions

Trials that read out recently, adding to the completed evidence base.

Comparative Study on the Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction Induced Experimentally in Diabetic Rats

CompletedPH IVAl-Azhar Universityn=502024

An Open Label Study to Evaluate the Effect of Avastin in Association With Chemotherapy on Progression-free Survival in Patients With Progressive Advanced/Metastatic Well-differentiated Digestive Endocrine Tumors of the Gastrointestinal Tract

CompletedPH IIHoffmann-La Rochen=832011

First International Randomized Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment

CompletedPH IIICollaborative Group for Adrenocortical Carcinoma Treatmentn=3042010

A Randomised Phase II Study Comparing Capecitabine Plus Streptozocin With or Without Cisplatin Chemotherapy as Treatment for Unresectable or Metastatic Neuroendocrine Tumors

CompletedPH IICambridge University Hospitals NHS Foundation Trustn=842009

Phase I Study of Combination Immunochemotherapy in Patients With Advanced Colorectal Carcinoma

CompletedPH IMemorial Sloan Kettering Cancer Centern=182002

Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms

CompletedPH IIEmory Universityn=351998

Research activity

4 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20122024
Major research themes8
Neuronal Plasticity2Alzheimer Disease1Cognitive Dysfunction1Diabetes Mellitus, Experimental1Diabetes Mellitus, Type 11Diabetes Mellitus, Type 21Hippocampus1Hyperglycemia1
Journals, researchers & institutions
Top journals
  • British journal of pharmacology1
  • Cells1
  • Current protocols1
  • Scientific reports1
Leading researchers
  • Aghanoori MR1
  • Ahmadiani A1
  • Al-Jarallah A1
  • Anjomani M1
  • Ansari MA1
  • Babiker FA1
  • Barzegar Behrooz A1
  • Eliassi A1
Leading institutions
free-text, unnormalised
  • Arak University of Medical Sciences1
  • Children Hospital Research Institute of Manitoba1
  • College of Medicine1
  • Cumming School of Medicine1
  • Department of Clinical Biochemistry1
  • Electrophysiology Research Center1

Related diseases

4 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Insulin

Studied across 9 of the same disease areas as Streptozocin in the shared literature.

9 shared diseases2 shared papers
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials